USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients

Published On 2023-09-04T13:55:00+05:30 | Updated On 4 Sep 2023 8:26 AM GMT

Overview

USV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment of type 2 diabetes in Indian patients.

USV's Liralin Range is launched in 3 SKU forms: Liralin, Liralin DP & Liralin M. Liralin M will be introduced soon.

Liralin contains Linagliptin 5 mg, whereas Liralin DP is an FDC of Linagliptin 5 mg & Dapagliflozin 10 mg. Liralin M is an FDC containing Linagliptin 5 mg & Metformin 1000 mg

Liralin DP is available at INR 19.9/- per tablet, while Liralin is priced at INR 11.9/- per tablet.

Linagliptin has multiple clinical and safety advantages, making it potentially an evergreen OAD agent as monotherapy and in combination with other agents

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751